These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
44. Prevalence of pathological duodenogastric reflux and the relationship between duodenogastric and duodenogastrooesophageal reflux in chronic gastrooesophageal reflux disease. Brillantino A; Monaco L; Schettino M; Torelli F; Izzo G; Cosenza A; Marano L; Di Martino N Eur J Gastroenterol Hepatol; 2008 Dec; 20(12):1136-43. PubMed ID: 18946360 [TBL] [Abstract][Full Text] [Related]
45. Medical treatment of gastroesophageal reflux disease. Ljubicić N; Habijanić E; Antić Z; Doko M; Kovacević I; Zovak M Acta Med Croatica; 1998; 52(2):133-8. PubMed ID: 9682502 [TBL] [Abstract][Full Text] [Related]
46. Increased swallowing frequency in GORD is likely to be caused by perception of reflux episodes. Hemmink GJ; Weusten BL; Bredenoord AJ; Timmer R; Smout AJ Neurogastroenterol Motil; 2009 Feb; 21(2):143-8. PubMed ID: 19019017 [TBL] [Abstract][Full Text] [Related]
47. What is left of the endoscopic antireflux devices? Jafri SM; Arora G; Triadafilopoulos G Curr Opin Gastroenterol; 2009 Jul; 25(4):352-7. PubMed ID: 19342950 [TBL] [Abstract][Full Text] [Related]
49. Demographic, clinical, and psychological characteristics of the heartburn groups classified using the Rome III criteria and factors associated with the responsiveness to proton pump inhibitors in the gastroesophageal reflux disease group. Lee KJ; Kwon HC; Cheong JY; Cho SW Digestion; 2009; 79(3):131-6. PubMed ID: 19307735 [TBL] [Abstract][Full Text] [Related]
50. On-demand therapy for gastroesophageal reflux disease. Metz DC; Inadomi JM; Howden CW; van Zanten SJ; Bytzer P Am J Gastroenterol; 2007 Mar; 102(3):642-53. PubMed ID: 17156134 [TBL] [Abstract][Full Text] [Related]
51. Gastrooesophageal reflux disease. Richter JE Best Pract Res Clin Gastroenterol; 2007; 21(4):609-31. PubMed ID: 17643904 [TBL] [Abstract][Full Text] [Related]
52. [Gastroesophageal reflux: alternatives to medical treatment]. Devière J Rev Med Brux; 2008 Sep; 29(4):373-8. PubMed ID: 18949991 [TBL] [Abstract][Full Text] [Related]
53. Proton pump inhibitors: the beginning of the end or the end of the beginning? Scarpignato C; Hunt RH Curr Opin Pharmacol; 2008 Dec; 8(6):677-84. PubMed ID: 18840545 [TBL] [Abstract][Full Text] [Related]
54. Management of respiratory symptoms associated with gastroesophageal reflux disease. Greason KL; Miller DL Minerva Chir; 2002 Dec; 57(6):781-7. PubMed ID: 12592220 [TBL] [Abstract][Full Text] [Related]
55. Diagnosis and management of laryngopharyngeal reflux disease. Remacle M; Lawson G Curr Opin Otolaryngol Head Neck Surg; 2006 Jun; 14(3):143-9. PubMed ID: 16728890 [TBL] [Abstract][Full Text] [Related]
56. Efficacy of esophageal impedance/pH monitoring in patients with refractory gastroesophageal reflux disease, on and off therapy. Pritchett JM; Aslam M; Slaughter JC; Ness RM; Garrett CG; Vaezi MF Clin Gastroenterol Hepatol; 2009 Jul; 7(7):743-8. PubMed ID: 19281866 [TBL] [Abstract][Full Text] [Related]
57. Treatment patterns and symptom control in patients with GERD: US community-based survey. Chey WD; Mody RR; Wu EQ; Chen L; Kothari S; Persson B; Beaulieu N; Lu M Curr Med Res Opin; 2009 Aug; 25(8):1869-78. PubMed ID: 19530980 [TBL] [Abstract][Full Text] [Related]